EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Lonafarnib improves cardiovascular function and survival in a mouse model of Hutchinson-Gilford progeria syndrome

Sae-Il Murtada, Nicole Mikush, Mo Wang, Pengwei Ren, Yuki Kawamura iD, Abhay B Ramachandra, David S Li, Demetrios T Braddock, George Tellides, Leslie B Gordon, Jay D Humphrey iD

eLife · 2023

DOI: 10.7554/elife.82728 ↗

Kurz gefasst

Fachartikel in der Zeitschrift eLife, 2023. Verfasst von Sae-Il Murtada und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biomedical Engineering, Yale University, New Haven, United States. Hauptthemen laut MEDLINE: Progeria. Die Arbeit wurde bisher 20-mal zitiert (Crossref) und nennt 46 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NHLBI NIH HHS, NIA NIH HHS, National Heart Lung & Blood Institute.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Clinical trials have demonstrated that lonafarnib, a farnesyltransferase inhibitor, extends the lifespan in patients afflicted by Hutchinson-Gilford progeria syndrome, a devastating condition that accelerates many characteristics of aging and results in premature death due to cardiovascular sequelae. The US Food and Drug Administration approved Zokinvy (lonafarnib) in November 2020 for treating these patients, yet a detailed examination of drug-associated effects on cardiovascular structure, properties, and function has remained wanting. In this paper, we report encouraging outcomes of daily post-weaning treatment with lonafarnib on the composition and biomechanical phenotype of elastic and muscular arteries as well as associated cardiac function in a well-accepted mouse model of progeria that exhibits severe perimorbid cardiovascular disease. Lonafarnib resulted in 100% survival of the treated progeria mice to the study end-point (time of 50% survival of untreated mice), with associated improvements in arterial structure and function working together to significantly reduce pulse wave velocity and improve left ventricular diastolic function. By contrast, neither treatment with the mTOR inhibitor rapamycin alone nor dual treatment with lonafarnib plus rapamycin improved outcomes over that achieved with lonafarnib monotherapy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

ProgeriaMiceAnimalsPulse Wave AnalysisPiperidinesSirolimusLamin Type ADibenzocycloheptenesPyridines

Stichwörter der Autor:innen

aortacardiac functionlamin Alonafarnibmousephysics of living systemsprogeriasurvival

Substanzen

PiperidinesSirolimusLamin Type AlonafarnibDibenzocycloheptenesPyridines

Autor:innen und Institutionen

  • Department of Biomedical Engineering, Yale University, New Haven, United States.
  • Translational Research Imaging Center, Yale University, New Haven, United States.
  • Department of Surgery, Yale University, New Haven, United States.
  • Department of Pathology, Yale University, New Haven, United States.
  • Vascular Biology and Therapeutics Program, Yale University, New Haven, United States.
  • Department of Pediatrics, Hasbro Children's Hospital and Warren Albert Medical School, Brown University, Providence, United States.

ORCID-Profile: Yuki Kawamura, Jay D Humphrey

Förderung

  • NHLBI NIH HHS
  • NIA NIH HHS
  • National Heart Lung & Blood Institute
  • National Institute on Aging
  • Inozyme Pharma

Zitieren

APA

Murtada, S. I., Mikush, N., Wang, M., Ren, P., Kawamura, Y., Ramachandra, A. B., Li, D. S., Braddock, D. T., Tellides, G., Gordon, L. B., & Humphrey, J. D. (2023). Lonafarnib improves cardiovascular function and survival in a mouse model of Hutchinson-Gilford progeria syndrome. eLife. https://doi.org/10.7554/elife.82728

Vancouver

Murtada SI, Mikush N, Wang M, Ren P, Kawamura Y, Ramachandra AB, et al. Lonafarnib improves cardiovascular function and survival in a mouse model of Hutchinson-Gilford progeria syndrome. eLife. 2023. doi:10.7554/elife.82728

BibTeX
@article{Murtada2023,
  author = {Murtada, Sae-Il and Mikush, Nicole and Wang, Mo and Ren, Pengwei and Kawamura, Yuki and Ramachandra, Abhay B and Li, David S and Braddock, Demetrios T and Tellides, George and Gordon, Leslie B and Humphrey, Jay D},
  title = {Lonafarnib improves cardiovascular function and survival in a mouse model of Hutchinson-Gilford progeria syndrome},
  journal = {eLife},
  year = {2023},
  doi = {10.7554/elife.82728}
}
Kostenlos starten →